Figure 2
The response after 2 courses of cladribine/Ara-C. At inclusion, the disease activity was active disease (AD) worse in 23 patients and AD stable in 4 patients. The disease score was similar in AD worse and AD stable patients.12 After 2 courses, disease activity was nonactive disease, AD stable in 2 patients, and AD better in 23 patients. The median score dropped from 12 at the start of therapy to 3 after 2 courses.
